FINWIRES · TerminalLIVE
FINWIRES

$BNTX

52 stories mentioning BNTXUpdated 1d ago

Every FINWIRES story that references BNTX, newest first.

What are analysts saying about BNTX?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on BNTX?

Insider Trading

Biontech Insider Sold Shares Worth $1,974,287, According to a Recent SEC Filing

Ugur Sahin, 10% Owner, Chief Executive Officer, on September 10, 2026, sold 20,500 shares in Biontech (BNTX) for $1,974,287. Following the Form 4 filing with the SEC, Sahin has control over a total of 39,906,320 ordinary shares of the company, with 688,209 shares held directly and 39,218,111 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1776985/000212397526000013/xslF345X05/wk-form4_1789161500.xml

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading

European equities traded in the US as American depositary receipts were trending lower late Thursday morning, declining 0.41% to 1,938.57 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and accommodations booking site trivago (TRVG), which advanced 1.6% and 1.1% respectively. They were followed by medical device maker EDAP TMS (FOCL) and 3D printer company Materialise (MTLS), which increased 1.2% and 0.8% respectively.The decliners from continental Europe were led by biotech firm Evaxion (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which lost 5% and 2.7% respectively. They were followed by biotech firm BioNTech (BNTX) and biopharmaceutical company Grifols (GRFS), which were down 1.8% and 1.7% respectively.The gainers from the UK were led by software firm Endava (DAVA) and biopharmaceutical company Akari Therapeutics (AKTX), which were up 2% and 1.6% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and pharmaceutical company AstraZeneca (AZN), which rose 1.2% and 1.5% respectively.The decliners from the UK and Ireland were led by mining company BHP Group (BHP) and biotech firm Trinity Biotech (TRIB), which fell 4.7% and 5.6% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Biodexa Pharmaceuticals (BDRX), which dropped 2.2% and 3% respectively.

$AKTX$AMRN$AZN$BDRX$BHP$BNTX$CLLS$DAVA$DBVT$EVAX$FOCL$GRFS$MTLS$TRIB$TRVG$VOD
Insider Trading

Biontech Insider Sold Shares Worth $7,889,055, According to a Recent SEC Filing

Ugur Sahin, 10% Owner, Chief Executive Officer, on September 03, 2026, sold 76,500 shares in Biontech (BNTX) for $7,889,055. Following the Form 4 filing with the SEC, Sahin has control over a total of 781,709 ordinary shares of the company, with 781,709 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1776985/000212397526000008/xslF345X05/wk-form4_1788898236.xml

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Tuesday morning, declining 0.46% to 1,968.02 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and telecommunications company Nokia (NOK), which rose 2.6% and 6.5% respectively. They were followed by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which were up 2.3% and 2.2% respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and internet browser company Opera (OPRA), which fell 4.9% and 2% respectively. They were followed by biopharmaceutical companies argenx (ARGX) and Cellectis (CLLS), which were down 2.2% and 0.3%, respectively.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and oil and gas company BP (BP), which increased 2% and 2.5% respectively. They were followed by mining company BHP Group (BHP) and oil and gas company Shell (SHEL), which advanced 3.4% and 2.5% respectively.The decliners from the UK and Ireland were led by software firm Endava (DAVA), which lost 6.2%. It was followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which dropped 3.6% and 3.4% respectively.

$AKTX$ARGX$AUTL$BHP$BNTX$BP$CLLS$DAVA$E$EQNR$EVAX$NOK$OPRA$SHEL$SLN
Research

BMO Capital Downgrades BioNTech to Market Perform From Outperform, Adjusts PT to $105 From $128

BioNTech SE (BNTX) has an average rating of overweight and mean price target of $119.05, according to analysts polled by FactSet.

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Marginally Higher in Friday Trading

European equities traded in the US as American depositary receipts were marginally higher late Friday morning, rising 0.08% to 1,976.36 on the S&P Europe Select ADR Index, which was up about 0.9% for the week so far.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and 3D printer company Materialise (MTLS), which rose 2% and 1.6%, respectively. They were followed by biotech firm BioNTech (BNTX), which gained 0.8%.The decliners from continental Europe were led by accommodations booking site trivago (TRVG) and oil and gas company Eni (E), which dropped 3.1% and 2.2%, respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company DBV Technologies (DBVT), which were down 2.1% and 1.7%, respectively.The gainers from the UK were led by telecommunications operator Vodafone Group (VOD) and oil and gas company Shell (SHEL), which advanced 2.2% and 0.9%, respectively. They were followed by oil and gas company BP (BP) and medical device maker Smith & Nephew (SNN), which were up 0.7% and 0.6%, respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and biotech firm Trinity Biotech (TRIB), which lost 4.5% and 3%, respectively. They were followed by software firm Endava (DAVA) and communications company WPP (WPP), which fell 2.6% and 2.2%, respectively.

$BNTX$BP$DBVT$E$EVAX$MREO$MTLS$NOK$NVO$SHEL$SNN$TRIB$TRVG$VOD
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.4%.The iShares Biotechnology ETF (IBB) fell 2.7%.In corporate news, BioNTech (BNTX) said it terminated its phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in people with colorectal cancer. The trial's independent safety board recommended discontinuing treatment and ending the trial, as further continuation was unlikely to change the efficacy outcome, the company said. Shares fell 8%.Eli Lilly (LLY) said the US Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. Lilly shares were down 0.9%.10x Genomics (TXG) said a Delaware federal jury awarded the company more than $4.8 million after finding that three patents held through its Scale Biosciences unit were infringed by Parse Biosciences, a subsidiary of Qiagen (QGEN). 10x Genomics shares were down 5.2%, and Qiagen was shedding 1.3%.Quoin Pharmaceuticals (QNRX) reported "positive" interim data from its ongoing phase 2/3 study of QRX003 in patients with netherton syndrome, and also a private placement financing of up to $50.0 million. Shares surged 18%.

$BNTX$LLY$QGEN$QNRX$TXG
BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall
US Markets

BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall

BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical trial of an experimental treatment of colorectal cancer, following a new recommendation from the study's independent data safety monitoring board.The German drugmaker was studying autogene cevumeran, an investigational mRNA-based cancer immunotherapy product, as an adjuvant therapy for patients suffering from resected stage II or stage III colorectal cancer in a phase 2 trial. BioNTech was jointly developing the candidate with Genentech, a member of the Roche Group.The decision to terminate the trial came after its safety board recommended discontinuing patient treatment and ending the study, according to BioNTech. The independent board, which also oversees the trial's integrity, identified a "numerical imbalance" in overall survival between treatment arms in patients and indicated further continuation was not expected to change the efficacy outcome, the company said Friday."While this outcome is not what we had envisioned for mRNA as a monotherapy in colorectal cancer, it provides scientific insight into the challenges of treating immunotherapy-insensitive tumor types with immune-suppressive microenvironments and will help inform the further development of investigational mRNA cancer immunotherapies," BioNTech Co-Founder and Chief Medical Officer Ozlem Tureci said in a statement.BioNTech's Nasdaq-listed shares fell 7.8% in afternoon trade. The stock has gained 8% in value so far this year.In October, the trial crossed its futility boundary, but the safety board had identified that the trial's data wasn't adequately "mature" to make reliable conclusions regarding its efficacy and there was insufficient follow-up time to evaluate its primary endpoint. BioNTech decided to continue the study at the time with no objection from the board.The company said Friday intends to continue a separate phase 2 study evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy for adjuvant pancreatic ductal adenocarcinoma, the most common and aggressive type of pancreatic cancer.Earlier this month, Moderna (MRNA) and Merck (MRK) said a late-stage trial of an experimental skin cancer treatment yielded positive topline results.On Thursday, BioNTech and Pfizer (PFE) said the US Food and Drug Administration approved the supplemental biologics license application for their 2026-2027 COVID-19 vaccine targeting the XFG variant.Price: $103.14, Change: $-8.26, Percent Change: -7.41%

$BNTX$MRK$MRNA$PFE
Sectors

Sector Update: Healthcare Stocks Decline Friday Afternoon

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.5%.The iShares Biotechnology ETF (IBB) dropped 2.5%.In corporate news, BioNTech (BNTX) said it terminated its phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in people with colorectal cancer. The trial's independent safety board recommended discontinuing treatment and ending the trial, as further continuation was unlikely to change the efficacy outcome, the company said. BioNTech shares fell 7.6%.Eli Lilly (LLY) said the US Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. Lilly shares were down 0.8%.Quoin Pharmaceuticals (QNRX) reported interim data from its ongoing phase 2/3 study of QRX003 4% lotion in patients with netherton syndrome and also entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to about $50 million in gross proceeds. Its shares surged about 29%.

$BNTX$LLY$QNRX
Sectors

Sector Update: Healthcare

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.4%.The iShares Biotechnology ETF (IBB) dropped 2.5%.In corporate news, BioNTech (BNTX) said it terminated its phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in people with colorectal cancer. The trial's independent safety board recommended discontinuing treatment and ending the trial, as further continuation was unlikely to change the efficacy outcome, the company said. Shares fell 7.5%.

$BNTX
Wire

Top Midday Stories: Warsh Says Inflation Data 'Concerning'; Advent, Stripe Drop $50 Billion Bid to Buy PayPal

All three major US stock indexes were up in late-morning trading Friday, as market participants parsed Federal Reserve Chairman Kevin Warsh's speech at the Jackson Hole Economic Policy Symposium in Wyoming.In the speech, Warsh said inflation is the more concerning part of the Fed's dual mandate while recommitting to the central bank's 2% policy target. The new chair also restated his belief that forward guidance can handcuff the Fed, preventing it from making key decisions.In company news, Advent and Stripe have abandoned their $50 billion bid to buy PayPal (PYPL), Bloomberg reported Friday, citing people familiar with the matter. PayPal shares were down 11.5% around midday.Marvell Technology (MRVL) reported fiscal Q2 adjusted earnings late Thursday of $0.94 per diluted share, up from $0.67 a year earlier and above the FactSet consensus estimate of $0.93. Fiscal Q2 revenue was $2.74 billion, up from $2.01 billion a year ago and above the FactSet consensus of $2.72 billion. For fiscal Q3, the company said it expects adjusted EPS of $1.10, plus or minus $0.05, on revenue of $3.15 billion, plus or minus 5%. Analysts polled by FactSet expect $1.08 and $3.04 billion, respectively. Marvell shares were down 8.2%.Chevron (CVX) is nearing a deal to expand its operations in Venezuela by adding two new heavy-oil fields to its portfolio, The Wall Street Journal reported Friday, citing people familiar with the matter. Halliburton (HAL) is also in discussions to provide its suite of equipment to oil producers in Venezuela, the report said, citing the people. Chevron and Halliburton shares were up 0.6% and 1%, respectively.BioNTech (BNTX) said Friday that it terminated its phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in patients with high-risk stage II or stage III colorectal cancer. The trial's independent safety board recommended discontinuing treatment and ending the trial, as further continuation was unlikely to change the efficacy outcome, the company said. BioNTech shares were down 7.5%.Amazon.com (AMZN) has signed a power purchase agreement in Germany and invested in four Swedish wind energy projects, the company said Friday. The e-commerce giant said it agreed to buy 600 megawatts of electricity from the planned Gennaker offshore wind farm in the Baltic Sea. Shares of Amazon were up 4.2%.Price: $54.41, Change: $-7.06, Percent Change: -11.49%

$AMZN$BNTX$CVX$HAL$MRVL$PYPL
Asia Markets

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

European equities traded in the US as American depositary receipts were marginally higher late Friday morning, edging up 0.03% to 1,963.94 on the S&P Europe Select ADR Index, which is off 0.5% for the week.From continental Europe, the gainers were led by accommodations booking site trivago (TRVG) and medical device maker EDAP TMS (FOCL), which rose 3.7% and 0.7% respectively. They were followed by consumer goods company Unilever (UL), which was up 0.7% respectively.The decliners from continental Europe were led by biotech firms BioNTech (BNTX) and DBV Technologies (DBVT), which fell 7.5% and 4.8% respectively. They were followed by 3D printer company Materialise (MTLS) and biopharmaceutical company Cellectis (CLLS), which were down 3.8% and 2.1% respectively.The gainers from the UK were led by lender HSBC (HSBC), which rose 1.1%, followed by alcoholic beverage company Diageo (DEO) and software firm Endava (DAVA), which advanced 0.5% and 0.1% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Autolus Therapeutics (AUTL), which dropped 3.4% and 2.8% respectively. They were followed by biotech firm Bicycle Therapeutics (BCYC) and medical device firm Trinity Biotech (TRIB), which lost 2.8% and 2.6% respectively.

$AUTL$BCYC$BDRX$BNTX$CLLS$DAVA$DBVT$DEO$FOCL$HSBC$MTLS$TRIB$TRVG$UL
Wire

BioNTech Shares Fall After Ending Phase 2 Colorectal Cancer Trial

BioNTech (BNTX) shares fell 9% in early Friday trading after the company said it has decided to terminate a phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in patients with high-risk stage II or stage III colorectal cancer.The trial's independent safety board recommended discontinuing treatment and ending the trial, saying further continuation was unlikely to change the efficacy outcome, according to the company.A separate phase 2 trial evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy for adjuvant pancreatic ductal adenocarcinoma is not affected and will continue as planned, the company said.Price: $101.50, Change: $-9.90, Percent Change: -8.89%

$BNTX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading

European equities traded in the US as American depositary receipts were trending lower late Thursday morning, declining 0.58% to 1,962.65 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by 3D printer company Materialise (MTLS) and software firm, SAP (SAP), which rose 4.6% and 3% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and semiconductor company Sequans Communications (SQNS), which were up 2.9% and 2.1% respectively.The decliners from continental Europe were led by pharmaceutical companies Novo Nordisk (NVO) and Sanofi (SNY), which lost 2.8% and 1.3% respectively. They were followed by biotech firm BioNTech (BNTX) and consumer goods company Unilever (UL), which dropped 1.2% and 1.1% respectively.The gainers from the UK were led by biotech firm Trinity Biotech (TRIB) and software company Endava (DAVA), which advanced 5.1% and 4.1% respectively. They were followed by biotech company Autolus Therapeutics (AUTL) and educational publisher Pearson (PSO), which increased 1.1% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Akari Therapeutics (AKTX), which fell 6.9% and 3% respectively. They were followed by biopharmaceutical company NuCana (NCNA) and pharmaceutical company GSK (GSK), which were down 2.6% and 1.9% respectively.

$AKTX$AUTL$BDRX$BNTX$CLLS$DAVA$GSK$MTLS$NCNA$NVO$PSO$SAP$SNY$SQNS$TRIB$UL
Asia Markets

European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Monday Trading

European equities traded in the US as American depositary receipts started the week slightly lower late Monday morning, declining 0.16% to 1,978.70 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by internet browser company Opera (OPRA) and consumer goods company Unilever (UL), which rose 1.9% and 1.8% respectively. They were followed by lender Banco Santander (SAN) and brewing company Anheuser-Busch InBev (BUD), which were up 1.2% and 1% respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and biotech firm BioNTech (BNTX), which dropped 5.1% and 4.2% respectively. They were followed by biopharmaceutical company argenx (ARGX) and telecommunications company Nokia (NOK), which were down 2.8% and 2.6% respectively.The gainers from the UK were led by communications group WPP (WPP) and education company Pearson (PSO), which advanced 3.4% and 2.1% respectively. They were followed by alcoholic beverage company Diageo (DEO) and hospitality company Intercontinental Hotels Group (IHG), which increased 2% each.The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which fell 5.5%. It was followed by biopharmaceutical company NuCana (NCNA) and biotech firm Autolus Therapeutics (AUTL), which lost 2% and 1% respectively.

$ARGX$AUTL$BDRX$BNTX$BUD$CLLS$DEO$IHG$NCNA$NOK$OPRA$PSO$SAN$UL$WPP
Asia Markets

European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading

European equities traded in the US as American depositary receipts were trending higher late Friday morning, rising 0.74% to 1,979.62 on the S&P Europe Select ADR Index, which is up 0.55% for the week so far.From continental Europe, the gainers were led by accommodations booking site trivago (TRVG) and biotech firm BioNTech (BNTX), which advanced 7.2% and 6.2%, respectively. They were followed by lender Banco Santander (SAN) and furniture maker Natuzzi (NTZ), which rose 2.9% and 1.7%, respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and oil and gas company Eni (E), which dropped 4.2% and 1.2%, respectively. They were followed by medical device maker EDAP TMS (FOCL) and healthcare tech company Royal Philips (PHG), which were off 1.1% and 0.4%, respectively.The gainers from the UK were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical firm Bicycle Therapeutics (BCYC), which climbed 6.6% and 4.3%, respectively. They were followed by mining company BHP Group (BHP) and lender Lloyds Banking Group (LYG), which were up 2.9% and 2.1%, respectively.The decliners from the UK and Ireland were led by telecommunications operator Vodafone Group (VOD) and biotech firm Autolus Therapeutics (AUTL), which lost 0.5% and 0.4% respectively. They were followed by alcoholic beverage company Diageo (DEO) and hospitality company Intercontinental Hotels Group (IHG), which were down 0.3% each.

$AUTL$BCYC$BHP$BNTX$CLLS$DEO$E$FOCL$IHG$LYG$NTZ$PHG$SAN$TRIB$TRVG$VOD
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

European equities traded in the US as American depositary receipts were tracking higher late Thursday morning, rising 0.52% to 1,977.10 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and biopharmaceutical company Cellectis (CLLS), which climbed 5.6% and 4.1%, respectively. They were followed by oil and gas company Eni (E) and semiconductor company Sequans Communications (SQNS), which advanced 2.3% and 0.6%, respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and biopharmaceutical company DBV Technologies (DBVT), which lost 4.5% and 3.2%, respectively. They were followed by medical device maker EDAP TMS (FOCL) and internet browser company Opera (OPRA), which were down 2.3% and 2.1%, respectively.The gainers from the UK were led by oil and gas companies BP (BP) and Shell (SHEL), which rose 3.7% and 1.9%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and lender HSBC (HSBC), which were up 1.4% and 0.9%, respectively.The decliners from the UK and Ireland were led by biopharamceutical firm Mereo BioPharma Group (MREO) and biotech firm Autolus Therapeutics (AUTL), which fell 3.8% and 3.4%, respectively. They were followed by biopharmaceutical company NuCana (NCNA) and software company Endava (DAVA), which were down 3.2% and 1.3%, respectively.

$AUTL$BDRX$BNTX$BP$CLLS$DAVA$DBVT$E$EVAX$FOCL$HSBC$MREO$NCNA$OPRA$SHEL$SQNS
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.68% to 1,973.64 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and biopharmaceutical company Grifols (GRFS), which advanced 24% and 5.6% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company argenx (ARGX), which rose 3.3% and 3% respectively.The decliners from continental Europe were led by internet browser company Opera (OPRA) and biotech firm Evaxion (EVAX), which fell 7.9% and 6% respectively. They were followed by accommodations booking site Trivago (TRVG) and telecommunications company Nokia (NOK), which were down 4.3% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and mining company BHP Group (BHP), which increased 9.2% and 4.5% respectively. They were followed by software firm Endava (DAVA) and biopharmaceutical company Bicycle Therapeutics (BCYC), which were up 4% and 3.4% respectively.The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 3.5% and 1.9% respectively. They were followed by insurance company Prudential (PUK) and medical device maker Smith & Nephew (SNN), which lost 1.3% and 1.1% respectively.

$ARGX$AUTL$BCYC$BDRX$BHP$BNTX$DAVA$EVAX$GRFS$NOK$OPRA$PUK$SNN$SQNS$TRIB$TRVG
Asia Markets

European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

European equities traded in the US as American depositary receipts were heading higher late Thursday morning, rising 0.85% to 1,947.79 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by accommodations booking site trivago (TRVG) and pharmaceutical company Ascendis Pharma (ASND), which advanced 4.8% and 2.2% respectively. They were followed by lender Banco Bilbao Vizcaya Argentaria (BBVA) and internet ad firm Criteo (CRTO), which were up 1.7% and 0.9% respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and internet browser company Opera (OPRA), which dropped 2.3% and 2.1% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and biotech company Evaxion (EVAX), which lost 1.8% and 1.3% respectively.The gainers from the UK were led by communications company WPP (WPP) and biotech firm Trinity Biotech (TRIB), which surged 26% and 11% respectively. They were followed by biotech company Autolus Therapeutics (AUTL) and alcoholic beverage company Diageo (DEO), which rose 5.3% and 4.4% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and medical device maker Smith & Nephew (SNN), which fell 4.4% and 1.9% respectively. They were followed by educational publisher Pearson (PSO) and biopharmaceutical company Mereo BioPharma Group (MREO), which were down 1.6% and 1.2% respectively.

$ASND$AUTL$BBVA$BDRX$BNTX$CLLS$CRTO$DEO$EVAX$MREO$OPRA$PSO$SNN$TRIB$TRVG$WPP
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) climbed 2%.In corporate news, AdaptHealth (AHCO) reported a Q2 loss Tuesday, with revenue below market expectations. The company also lowered its full-year 2026 sales guidance. Its shares fell 37%.AbbVie (ABBV) has commenced a $10 billion investment-grade bond sale to help finance its pending acquisition of Apogee Therapeutics (APGE), Bloomberg reported. The offering, which includes bonds maturing in two to 40 years, has drawn about $63 billion of peak demand, the report said. AbbVie shares were down 0.4%.BioNTech (BNTX) shares shed 0.5% after it reported a wider Q2 adjusted loss and lower revenue, and cut its 2026 revenue guidance.Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both pharmaceutical giants logged better-than-expected sales for Q2. Merck shares rose 0.6%, and Pfizer added 1.5%.

$ABBV$AHCO$BNTX$MRK$PFE

Showing 1-20 of 52

Track with the FINWIRES app suite

FolioX
FolioX
Track BNTX in your portfolio
WheelAI
WheelAI
Analyze BNTX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on BNTX